8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
GeoVax Labs, Inc.(GOVX)Earnings, Financials & Key Ratios
GOVX•NASDAQ
Price updated Jun 19, 2026
AboutGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.Show more
- Revenue$2M-37.1%
- EBITDA-$22M+13.6%
- Net Income-$21M+14.1%
- EPS (Diluted)-22.40+81.4%
- Gross Margin100%+2.5%
- EBITDA Margin-869.34%-37.2%
- Operating Margin-869.34%-36.7%
- Net Margin-862.34%-36.4%
- ROE-0%+100.0%
GOVX Key Insights
GeoVax Labs, Inc. (GOVX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Profits declining 48.6% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GOVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GOVX Price & Volume
GeoVax Labs, Inc. (GOVX) stock price & volume — 10-year historical chart
Loading chart...
GOVX Growth Metrics
GeoVax Labs, Inc. (GOVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.25%
5 Years6.42%
3 Years212.55%
TTM-84.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM12.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.01%
Return on Capital
10 Years-210.54%
5 Years-190.13%
3 Years-210.13%
Last Year-0%
GOVX Peer Comparison
GeoVax Labs, Inc. (GOVX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 INO | 770.49M | 1.12 | -0.62 | -69.99% | -6.66% | 0.39 | ||
 VXRT | 133.33M | 0.55 | 7.87 | 7.27% | 14.51% | 61.43% | 0.10 |
Compare GOVX vs Peers
GeoVax Labs, Inc. (GOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GOVX Income Statement
GeoVax Labs, Inc. (GOVX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.08M | 963K | 1.18M | 1.82M | 385.5K | 81.53K | 0 | 3.95M | 2.49M | 852.28K |
Revenue Growth % | 29.72% | -10.44% | 22.11% | 55.09% | -78.86% | -78.85% | -100% | - | -37.06% | -84.76% |
Cost of Goods Sold | 2.02M | 1.88M | 0 | 0 | 0 | 9.12M | 20.72M | 95.37K | 0 | -21.65K |
COGS % of Revenue | 187.61% | 195.08% | - | - | - | 11190.88% | - | 2.41% | - | - |
Gross Profit | -942.08K▲ 0% | -915.65K▲ 2.8% | 1.18M▲ 228.4% | 1.82M▲ 55.1% | 385.5K▼ 78.9% | -9.04M▼ 2445.5% | -20.72M▼ 129.2% | 3.86M▲ 118.6% | 2.49M▼ 35.5% | 873.93K▲ 0% |
Gross Margin % | -87.61% | -95.08% | 100% | 100% | 100% | -11090.88% | - | 97.59% | 100% | 102.54% |
Gross Profit Growth % | 17.5% | 2.81% | 228.42% | 55.09% | -78.86% | -2445.51% | -129.16% | 118.62% | -35.5% | - |
Operating Expenses | 3.25M | 3.53M | 3.55M | 4.64M | 19.13M | 4.99M | 6.02M | 29M | 24.13M | 22.39M |
OpEx % of Revenue | 302.22% | 366.15% | 301.76% | 254.46% | 4962.72% | 6116.59% | - | 733.42% | 969.34% | - |
Selling, General & Admin | 1.23M | 1.65M | 1.64M | 2.2M | 3.58M | 4.99M | 5.95M | 5.39M | 6.01M | 5.72M |
SG&A % of Revenue | 114.61% | 171.03% | 139.27% | 120.42% | 927.92% | 6116.59% | - | 136.18% | 241.31% | - |
Research & Development | 2.02M | 1.88M | 1.91M | 2.44M | 15.55M | 9.12M | 20.72M | 23.71M | 18.12M | 16.67M |
R&D % of Revenue | 187.61% | 195.12% | 162.49% | 134.04% | 4034.79% | 11190.88% | - | 599.65% | 728.02% | - |
Other Operating Expenses | 0 | 3K | 0 | 0 | 0 | -9.12M | -20.65M | -95.37K | 0 | 0 |
Operating Income | -2.17M▲ 0% | -2.56M▼ 17.9% | -2.37M▲ 7.4% | -2.82M▼ 18.7% | -18.75M▼ 565.5% | -14.03M▲ 25.2% | -26.74M▼ 90.6% | -25.14M▲ 6.0% | -21.64M▲ 13.9% | -21.51M▲ 0% |
Operating Margin % | -202.22% | -266.15% | -201.76% | -154.46% | -4862.72% | -17207.47% | - | -635.83% | -869.34% | -2523.43% |
Operating Income Growth % | 33.57% | -17.87% | 7.43% | -18.73% | -565.5% | 25.16% | -90.63% | 5.98% | 13.94% | - |
EBITDA | -2.15M | -2.54M | -2.36M | -2.8M | -18.71M | -13.97M | -26.67M | -25.05M | -21.64M | -21.51M |
EBITDA Margin % | -199.62% | -264.09% | -201.05% | -153.38% | -4852.72% | -17138.43% | - | -633.42% | -869.34% | -2524% |
EBITDA Growth % | 33.85% | -18.49% | 7.04% | -18.32% | -568.8% | 25.31% | -90.87% | 6.07% | 13.61% | 12.46% |
D&A (Non-Cash Add-back) | 28.03K | 19.8K | 8.35K | 19.66K | 38.52K | 56.28K | 74.17K | 95.37K | 0 | -4.84K |
EBIT | -2.17M | -2.56M | -2.37M | -2.81M | -18.57M | -14.03M | -26.74M | -24.97M | -21.64M | -21.55M |
Net Interest Income | 4.29K | 2.62K | 1.86K | -141.25K | 3.45K | 7.44K | 776.18K | 151.98K | 174.28K | 137.72K |
Interest Income | 4.29K | 5.21K | 6.36K | 2.27K | 4.74K | 7.44K | 776.18K | 173.36K | 174.28K | 137.72K |
Interest Expense | 0 | 2.59K | 4.5K | 143.52K | 1.29K | 0 | 0 | 21.38K | 0 | 0 |
Other Income/Expense | 4.29K | 2.62K | 1.86K | -141.25K | 175.51K | 7.44K | 776.18K | 151.98K | 174.28K | 137.72K |
Pretax Income | -2.17M▲ 0% | -2.56M▼ 18.0% | -2.37M▲ 7.4% | -2.96M▼ 24.8% | -18.57M▼ 527.8% | -14.02M▲ 24.5% | -25.97M▼ 85.2% | -24.99M▲ 3.8% | -21.46M▲ 14.1% | -21.37M▲ 0% |
Pretax Margin % | -201.82% | -265.84% | -201.6% | -162.21% | -4817.19% | -17198.35% | - | -631.98% | -862.34% | -2507.27% |
Income Tax | 0 | 5.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -0.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.17M▲ 0% | -2.56M▼ 18.0% | -2.37M▲ 7.4% | -2.96M▼ 24.8% | -18.57M▼ 527.8% | -14.02M▲ 24.5% | -25.97M▼ 85.2% | -24.99M▲ 3.8% | -21.46M▲ 14.1% | -21.37M▲ 0% |
Net Margin % | -201.82% | -265.84% | -201.6% | -162.21% | -4817.19% | -17198.35% | - | -631.98% | -862.34% | -2507.27% |
Net Income Growth % | 33.67% | -17.96% | 7.4% | -24.78% | -527.79% | 24.5% | -85.2% | 3.75% | 14.11% | 12.78% |
Net Income (Continuing) | -2.17M | -2.56M | -2.37M | -2.96M | -18.57M | -14.02M | -25.97M | -24.99M | -21.46M | -21.37M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -21.25▲ 0% | -25.25▼ 18.8% | -23.50▲ 6.9% | -29.00▼ 23.4% | -182.50▼ 529.3% | -138.00▲ 24.4% | -255.50▼ 85.1% | -120.50▲ 52.8% | -22.40▲ 81.4% | -10.64▲ 0% |
EPS Growth % | 34.11% | -18.82% | 6.93% | -23.4% | -529.31% | 24.38% | -85.14% | 52.84% | 81.41% | 79.01% |
EPS (Basic) | -21.25 | -25.25 | -23.50 | -29.00 | -182.50 | -138.00 | -255.50 | -120.50 | -22.40 | - |
Diluted Shares Outstanding | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 207.48K | 958.44K | 2.01M |
Basic Shares Outstanding | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 207.48K | 958.44K | 2.01M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GOVX Balance Sheet
GeoVax Labs, Inc. (GOVX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 448.07K | 620K | 447.26K | 10.23M | 11.63M | 28.94M | 7.89M | 7.93M | 5.31T | 2.43M |
Cash & Short-Term Investments | 312.73K | 260K | 283.34K | 9.88M | 11.42M | 27.61M | 6.45M | 5.51M | 5.51M | 1.27M |
Cash Only | 312.73K | 260K | 283.34K | 9.88M | 11.42M | 27.61M | 6.45M | 5.51M | 5.51M | 1.27M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 59.76K | 121.81K | 68.6K | 182.66K | 49.01K | 0 | 0 | 659.41K | 0 | 0 |
Days Sales Outstanding | 20.28 | 46.17 | 21.29 | 36.56 | 46.4 | - | - | 60.86 | - | 57.04 |
Inventory | 0 | -121.81K | 0 | 0 | -49.01K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | -352 | 48.76K | 0 | 0 | 0 | 2.23T | 0 |
Total Non-Current Assets | 42.16K | 22K | 21.62K | 159K | 168K | 2.41M | 1.4M | 220.98K | 1.03T | 551.09K |
Property, Plant & Equipment | 31.15K | 22K | 10.61K | 159K | 168K | 2.41M | 209.69K | 149.97K | 940.27B | 481.14K |
Fixed Asset Turnover | 34.52x | 43.77x | 110.87x | 11.47x | 2.29x | 0.03x | - | 26.37x | 0.00x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 80K | 70K | 60K | 50K | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 11.01K | 0 | 11.01K | 0 | 0 | -80K | 1.12M | 11.01K | 86.95B | 69.95K |
Total Assets | 490.24K▲ 0% | 642K▲ 31.0% | 468.88K▼ 27.0% | 10.39M▲ 2116.8% | 11.8M▲ 13.5% | 31.35M▲ 165.7% | 9.28M▼ 70.4% | 8.16M▼ 12.1% | 6.34T▲ 77758254.8% | 2.98M▲ 0% |
Asset Turnover | 2.19x | 1.50x | 2.51x | 0.18x | 0.03x | 0.00x | - | 0.48x | 0.00x | 0.00x |
Asset Growth % | -19.66% | 30.96% | -26.97% | 2116.77% | 13.5% | 165.73% | -70.39% | -12.14% | 77758254.81% | 77758173.58% |
Total Current Liabilities | 811.29K | 1.62M | 2.02M | 810.31K | 5.44M | 4.75M | 3.52M | 3.11M | 1.94T | 2.29M |
Accounts Payable | 77.58K | 125.86K | 152.65K | 267.7K | 2.06M | 1.75M | 2.8M | 1.85M | 790.75K | 1.43M |
Days Payables Outstanding | 14.04 | 24.45 | - | - | - | 69.92 | 49.37 | 7.08K | - | -21.2K |
Short-Term Debt | 0 | 260.42K | 12.5K | 183.33K | 0 | 0 | 0 | 0 | 263.13B | 197.47K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 270.88K | 1.67T | 663.21K |
Current Ratio | 0.55x | 0.38x | 0.22x | 12.63x | 2.14x | 6.10x | 2.24x | 2.55x | 2.74x | 1.06x |
Quick Ratio | 0.55x | 0.46x | 0.22x | 12.63x | 2.15x | 6.10x | 2.24x | 2.55x | 2.74x | 1.06x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 21.25K |
Total Non-Current Liabilities | 0 | 39.58K | 27.24K | 14.74K | 2M | 0 | 0 | 0 | 580.03B | 197.1K |
Long-Term Debt | 0 | 39.58K | 27.24K | 14.74K | 0 | 0 | 0 | 0 | 580.03B | 197.1K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 2M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 811.29K | 1.66M | 2.04M | 825K | 7.43M | 4.75M | 3.52M | 3.11M | 2.52T | 2.49M |
Total Debt | 0 | 300K | 39.74K | 198.06K | 0 | 0 | 0 | 0 | 843.17B | 394.57K |
Net Debt | -312.73K | 40K | -243.6K | -9.69M | -11.42M | -27.61M | -6.45M | -5.51M | 843.16B | -877.19K |
Debt / Equity | - | - | - | 0.02x | - | - | - | - | 0.22x | 0.80x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.04x |
Interest Coverage | - | -987.45x | -526.39x | -19.61x | -14439.37x | - | - | -1168.23x | - | - |
Total Equity | -321.06K▲ 0% | -1.02M▼ 218.3% | -1.57M▼ 54.1% | 9.57M▲ 707.7% | 4.36M▼ 54.4% | 26.6M▲ 509.8% | 5.76M▼ 78.3% | 5.05M▼ 12.4% | 3.83T▲ 75767068.1% | 493.77K▲ 0% |
Equity Growth % | -233.57% | -218.32% | -54.07% | 707.73% | -54.42% | 509.81% | -78.33% | -12.4% | 75767068.1% | 75767154.23% |
Book Value per Share | -3.16 | -10.06 | -15.50 | 94.19 | 42.94 | 261.82 | 56.73 | 24.33 | 999999.00 | 0.25 |
Total Shareholders' Equity | -321.06K | -1.02M | -1.57M | 9.57M | 4.36M | 26.6M | 5.76M | 5.05M | 3.83T | 493.77K |
Common Stock | 106.74K | 218.9K | 300 | 3.83K | 6.38K | 26.34K | 1.98K | 10.54K | 1.73K | 2.82K |
Retained Earnings | -37.92M | -40.48M | -42.85M | -45.81M | -64.38M | -78.4M | -104.36M | -129.36M | -150.82T | -156.08M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -663.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GOVX Cash Flow Statement
GeoVax Labs, Inc. (GOVX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.69M | -1.54M | -1.4M | -2.75M | -11.2M | -19.03M | -25.17M | -24.68M | -21.47M | -19.05M |
Operating CF Margin % | -157.03% | -160.23% | -118.93% | -150.83% | -2904.38% | -23342.5% | - | -623.97% | -862.7% | - |
Operating CF Growth % | 13.24% | 8.61% | 9.37% | -96.68% | -307.06% | -69.97% | -32.28% | 1.98% | 12.97% | -13.41% |
Net Income | -2.17M | -2.56M | -2.37M | -2.96M | -18.57M | -14.02M | -25.97M | -24.99M | -21.46M | -21.37M |
Depreciation & Amortization | 28.03K | 19.8K | 8.35K | 19.66K | 38.52K | 56.28K | 74.17K | 95.37K | 68.76K | 63.91K |
Stock-Based Compensation | 57.22K | 469.72K | 327.5K | 64.46K | 369.99K | 902.07K | 1.07M | 528.64K | 1.12M | 1.04M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -3.65M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -296.48K | 18.26K | 0 | 124.19K | 37.77K | 3.65M | 0 | 0 | 0 | 0 |
Working Capital Changes | 396.45K | 527.54K | 636.28K | -806 | 6.93M | -5.97M | -356K | -307.23K | -1.19M | 1.22M |
Change in Receivables | -31.68K | -62.06K | 53.21K | -114.06K | 133.66K | 49.01K | 0 | -659.41K | 659.41K | 1.5M |
Change in Inventory | 0 | 0 | 0 | 114.06K | -133.66K | -49.01K | 0 | 0 | 0 | 0 |
Change in Payables | 441.44K | 553.12M | 639.28K | 137.96B | 6.81T | -2.69M | -1.23M | -412.55K | 0 | -690.63K |
Cash from Investing | -4.35K | 0 | -7.61K | -156.79K | -47.72K | -134.26K | -48.95K | -20.65K | -27.61K | -10.72K |
Capital Expenditures | -4.35K | 0 | -7.61K | -156.79K | -47.72K | -134.26K | -48.95K | -20.65K | -27.61K | -10.72K |
CapEx % of Revenue | 0.4% | - | 0.65% | 8.6% | 12.38% | 164.68% | - | 0.52% | 1.11% | 1.26% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.55M | 1.49M | 1.43M | 12.51M | 12.78M | 35.35M | 4.06M | 23.75M | 19.08M | 12.89M |
Debt Issued (Net) | 0 | 300K | -10.26K | 1.05M | -27.86K | 0 | 0 | -15K | 0 | 0 |
Equity Issued (Net) | 0 | 1.19M | 1.44M | 11.46M | 9.41M | 27.73M | 4.06M | 21.4M | 19.08M | 12.89M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -1K | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.55M | 0 | 0 | 2.5K | 3.4M | 7.63M | 0 | 2.37M | 0 | 0 |
Net Change in Cash | -141.3K▲ 0% | -53.03K▲ 62.5% | 23.64K▲ 144.6% | 9.6M▲ 40511.1% | 1.54M▼ 84.0% | 16.19M▲ 951.2% | -21.16M▼ 230.7% | -945.65K▲ 95.5% | -2.42M▼ 156.0% | -6.17M▲ 0% |
Free Cash Flow | -1.69M▲ 0% | -1.54M▲ 8.8% | -1.41M▲ 8.9% | -2.91M▼ 106.8% | -11.24M▼ 286.7% | -19.16M▼ 70.4% | -25.22M▼ 31.6% | -24.7M▲ 2.1% | -21.5M▲ 12.9% | -19.05M▲ 0% |
FCF Margin % | -157.43% | -160.23% | -119.58% | -159.42% | -2916.76% | -23507.18% | - | -624.5% | -863.81% | -2234.71% |
FCF Growth % | 90.49% | 8.85% | 8.87% | -106.77% | -286.75% | -70.44% | -31.61% | 2.09% | 12.94% | 23.75% |
FCF per Share | -16.66 | -15.19 | -13.84 | -28.62 | -110.68 | -188.64 | -248.27 | -119.03 | -22.43 | -9.48 |
FCF Conversion (FCF/Net Income) | 0.78x | 0.60x | 0.59x | 0.93x | 0.60x | 1.36x | 0.97x | 0.99x | 1.00x | 0.89x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GOVX Key Ratios
GeoVax Labs, Inc. (GOVX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -74% | -266.6% | -90.57% | -160.47% | -462.31% | -0% | -0% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -0% | -0% |
Gross Margin | -87.61% | -95.08% | 100% | 100% | 100% | -11090.88% | - | 97.59% | 100% | 102.54% |
Net Margin | -201.82% | -265.84% | -201.6% | -162.21% | -4817.19% | -17198.35% | - | -631.98% | -862.34% | -2507.27% |
Debt / Equity | - | - | - | 0.02x | - | - | - | - | 0.22x | 0.80x |
Interest Coverage | - | -987.45x | -526.39x | -19.61x | -14439.37x | - | - | -1168.23x | - | - |
FCF Conversion | 0.78x | 0.60x | 0.59x | 0.93x | 0.60x | 1.36x | 0.97x | 0.99x | 1.00x | 0.89x |
Revenue Growth | 29.72% | -10.44% | 22.11% | 55.09% | -78.86% | -78.85% | -100% | - | -37.06% | -84.76% |
Related:GOVX Dividend History·GOVX Revenue History·GOVX Price History·GOVX P/E History·GOVX Financial Ratios·GOVX Institutional Holders
GOVX SEC Filings & Documents
GeoVax Labs, Inc. (GOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
GOVX Frequently Asked Questions
GeoVax Labs, Inc. (GOVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GeoVax Labs, Inc. (GOVX) reported $0.9M in revenue for fiscal year 2025. This represents a 807% increase from $0.1M in 1996.
GeoVax Labs, Inc. (GOVX) saw revenue decline by 37.1% over the past year.
GeoVax Labs, Inc. (GOVX) reported a net loss of $21.4M for fiscal year 2025.
Dividend & Returns
GeoVax Labs, Inc. (GOVX) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
GeoVax Labs, Inc. (GOVX) had negative free cash flow of $19.0M in fiscal year 2025, likely due to heavy capital investments.